Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab in Postmenopausal Women in India With Osteoporosis and a High Risk of Fracture
NCT06079476Phase 4Completed
- Sponsor
- Amgen
- Start
- Oct 2023
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of romosozumab in osteoporosis, sponsored by Amgen. Started Oct 2023; status: completed.
02
Drugs
romosozumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT06079476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06079476.